Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells

A number of growth factors, including members of the fibroblast growth factor (FGF) family - hepatocyte growth factor, vascular endothelial growth factor and heparin-binding epidermal growth factor - are dependent on heparan sulphate (HS) for biological activity mediated through their high-affinity...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 1997-01, Vol.75 (1), p.9-16
Hauptverfasser: Jayson, GC, Gallagher, JT
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 16
container_issue 1
container_start_page 9
container_title British journal of cancer
container_volume 75
creator Jayson, GC
Gallagher, JT
description A number of growth factors, including members of the fibroblast growth factor (FGF) family - hepatocyte growth factor, vascular endothelial growth factor and heparin-binding epidermal growth factor - are dependent on heparan sulphate (HS) for biological activity mediated through their high-affinity signal-transducing receptors. This obligate requirement for HS prompted the search for antagonists of HS function that could be used as anti-growth factor drugs for the treatment of cancer. Basic FGF (bFGF) was the focus of this study. Caco-2, a human colon carcinoma cell line, was adapted to growth in serum-free medium so that investigation of its growth factor requirements for growth and migration could be performed in defined conditions (Jayson GC, Evans GS, Pemberton PW, Lobley RW, Allen T 1994, Cancer Res, 54, 5718-5723). This cell line multiplied and moved in a dose-dependent manner in response to bFGF. Here, we show that the mitogenic response to bFGF is dependent on the presence of heparan sulphate. A library of heparin oligosaccharides with uniform composition but variable length was generated [general formula [IdoA(2S)-GlcNS(6S)n], and oligosaccharides of defined lengths were tested for their ability to inhibit the biological activity of bFGF. While intact heparin and heparin-derived fragments of 12 monosaccharide units did not affect bFGF-induced cell division or bFGF-induced cell migration, octasaccharides and decasaccharides potently inhibited the bFGF-induced growth and migration responses. In particular, octasaccharides completely inhibited these biological activities at 10 microg ml-, a clinically achievable and tolerable concentration. This study shows that the length of an oligosaccharide determines its ability to block the biological activity of bFGF. The observation that the biological activity of cell-surface heparan sulphate can be antagonized in this way in a human carcinoma cell line suggests that oligosaccharides should be investigated further as anti-growth factor agents for the treatment of cancer. In addition, the results suggest that the clinical evaluation of low-molecular weight heparin (LMWH) as an anti-cancer agent might benefit from subfractionation of the LMWH, to remove oligosaccharides of 12 or more residues.
doi_str_mv 10.1038/bjc.1997.3
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2222707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78787388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-b3da81a54d8e38b1dcff2c94f6557172ca8ca2ea6ef0838720019d88c2e878cf3</originalsourceid><addsrcrecordid>eNptkc1rGzEQxUVoSJ20l9xbdAg9NKyjD28k5RAoJk4CgVwaehSzWsmWWUuutBvIfx8tNqaF6CIN78d7oxmEzimZUsLlVbM2U6qUmPIjNKE1ZxWVTHxCE0KIqIhi5DM6zXldSkWkOEEnqjxrxSboz4PdQvIBx84vYwZjVqVsbb7BPqx84_uYMo4O9yuLGx-7uPQGOgym96--fxulZnG_wDHgOZhYMWxs1-Uv6NhBl-3X_X2GXhZ3v-cP1dPz_eP811Nlaib6quEtSAr1rJWWy4a2xjlm1Mxd17WgghmQBpiFa-uI5FIwQqhqpTTMSiGN42fodue7HZqNbY0NfYJOb5PfQHrTEbz-Xwl-pZfxVbNyBBHF4MfeIMW_g8293vg8fgGCjUPWouQILmUBf-5Ak2LOybpDCCV6XIMua9DjGjQv8Ld_2zqg-7kX_WKvQy7jdAmC8fmAsZpTNRubu9xhuShhaZNexyGFMtCPQ7_v6AD9kOzBrSAjwfk7D8yqBQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78787388</pqid></control><display><type>article</type><title>Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Jayson, GC ; Gallagher, JT</creator><creatorcontrib>Jayson, GC ; Gallagher, JT</creatorcontrib><description>A number of growth factors, including members of the fibroblast growth factor (FGF) family - hepatocyte growth factor, vascular endothelial growth factor and heparin-binding epidermal growth factor - are dependent on heparan sulphate (HS) for biological activity mediated through their high-affinity signal-transducing receptors. This obligate requirement for HS prompted the search for antagonists of HS function that could be used as anti-growth factor drugs for the treatment of cancer. Basic FGF (bFGF) was the focus of this study. Caco-2, a human colon carcinoma cell line, was adapted to growth in serum-free medium so that investigation of its growth factor requirements for growth and migration could be performed in defined conditions (Jayson GC, Evans GS, Pemberton PW, Lobley RW, Allen T 1994, Cancer Res, 54, 5718-5723). This cell line multiplied and moved in a dose-dependent manner in response to bFGF. Here, we show that the mitogenic response to bFGF is dependent on the presence of heparan sulphate. A library of heparin oligosaccharides with uniform composition but variable length was generated [general formula [IdoA(2S)-GlcNS(6S)n], and oligosaccharides of defined lengths were tested for their ability to inhibit the biological activity of bFGF. While intact heparin and heparin-derived fragments of 12 monosaccharide units did not affect bFGF-induced cell division or bFGF-induced cell migration, octasaccharides and decasaccharides potently inhibited the bFGF-induced growth and migration responses. In particular, octasaccharides completely inhibited these biological activities at 10 microg ml-, a clinically achievable and tolerable concentration. This study shows that the length of an oligosaccharide determines its ability to block the biological activity of bFGF. The observation that the biological activity of cell-surface heparan sulphate can be antagonized in this way in a human carcinoma cell line suggests that oligosaccharides should be investigated further as anti-growth factor agents for the treatment of cancer. In addition, the results suggest that the clinical evaluation of low-molecular weight heparin (LMWH) as an anti-cancer agent might benefit from subfractionation of the LMWH, to remove oligosaccharides of 12 or more residues.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1997.3</identifier><identifier>PMID: 9000592</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Animals ; Antineoplastic agents ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Caco-2 Cells ; Cancer Research ; Cattle ; Cell Division - drug effects ; Cell Movement - drug effects ; Chlorates - pharmacology ; Chromatography, Gel ; Drug Resistance ; Epidemiology ; experimental-oncology ; Fibroblast Growth Factor 2 - antagonists &amp; inhibitors ; Fibroblast Growth Factor 2 - pharmacology ; General aspects ; Glycosaminoglycans - metabolism ; Heparin - analogs &amp; derivatives ; Heparin - chemistry ; Heparitin Sulfate - pharmacology ; Humans ; Medical sciences ; Molecular Medicine ; Oligosaccharides - chemical synthesis ; Oligosaccharides - isolation &amp; purification ; Oligosaccharides - pharmacology ; Oncology ; Pharmacology. Drug treatments</subject><ispartof>British journal of cancer, 1997-01, Vol.75 (1), p.9-16</ispartof><rights>Cancer Research Campaign 1997</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-b3da81a54d8e38b1dcff2c94f6557172ca8ca2ea6ef0838720019d88c2e878cf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222707/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222707/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2727,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2531947$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9000592$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jayson, GC</creatorcontrib><creatorcontrib>Gallagher, JT</creatorcontrib><title>Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>A number of growth factors, including members of the fibroblast growth factor (FGF) family - hepatocyte growth factor, vascular endothelial growth factor and heparin-binding epidermal growth factor - are dependent on heparan sulphate (HS) for biological activity mediated through their high-affinity signal-transducing receptors. This obligate requirement for HS prompted the search for antagonists of HS function that could be used as anti-growth factor drugs for the treatment of cancer. Basic FGF (bFGF) was the focus of this study. Caco-2, a human colon carcinoma cell line, was adapted to growth in serum-free medium so that investigation of its growth factor requirements for growth and migration could be performed in defined conditions (Jayson GC, Evans GS, Pemberton PW, Lobley RW, Allen T 1994, Cancer Res, 54, 5718-5723). This cell line multiplied and moved in a dose-dependent manner in response to bFGF. Here, we show that the mitogenic response to bFGF is dependent on the presence of heparan sulphate. A library of heparin oligosaccharides with uniform composition but variable length was generated [general formula [IdoA(2S)-GlcNS(6S)n], and oligosaccharides of defined lengths were tested for their ability to inhibit the biological activity of bFGF. While intact heparin and heparin-derived fragments of 12 monosaccharide units did not affect bFGF-induced cell division or bFGF-induced cell migration, octasaccharides and decasaccharides potently inhibited the bFGF-induced growth and migration responses. In particular, octasaccharides completely inhibited these biological activities at 10 microg ml-, a clinically achievable and tolerable concentration. This study shows that the length of an oligosaccharide determines its ability to block the biological activity of bFGF. The observation that the biological activity of cell-surface heparan sulphate can be antagonized in this way in a human carcinoma cell line suggests that oligosaccharides should be investigated further as anti-growth factor agents for the treatment of cancer. In addition, the results suggest that the clinical evaluation of low-molecular weight heparin (LMWH) as an anti-cancer agent might benefit from subfractionation of the LMWH, to remove oligosaccharides of 12 or more residues.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Caco-2 Cells</subject><subject>Cancer Research</subject><subject>Cattle</subject><subject>Cell Division - drug effects</subject><subject>Cell Movement - drug effects</subject><subject>Chlorates - pharmacology</subject><subject>Chromatography, Gel</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>experimental-oncology</subject><subject>Fibroblast Growth Factor 2 - antagonists &amp; inhibitors</subject><subject>Fibroblast Growth Factor 2 - pharmacology</subject><subject>General aspects</subject><subject>Glycosaminoglycans - metabolism</subject><subject>Heparin - analogs &amp; derivatives</subject><subject>Heparin - chemistry</subject><subject>Heparitin Sulfate - pharmacology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Molecular Medicine</subject><subject>Oligosaccharides - chemical synthesis</subject><subject>Oligosaccharides - isolation &amp; purification</subject><subject>Oligosaccharides - pharmacology</subject><subject>Oncology</subject><subject>Pharmacology. Drug treatments</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkc1rGzEQxUVoSJ20l9xbdAg9NKyjD28k5RAoJk4CgVwaehSzWsmWWUuutBvIfx8tNqaF6CIN78d7oxmEzimZUsLlVbM2U6qUmPIjNKE1ZxWVTHxCE0KIqIhi5DM6zXldSkWkOEEnqjxrxSboz4PdQvIBx84vYwZjVqVsbb7BPqx84_uYMo4O9yuLGx-7uPQGOgym96--fxulZnG_wDHgOZhYMWxs1-Uv6NhBl-3X_X2GXhZ3v-cP1dPz_eP811Nlaib6quEtSAr1rJWWy4a2xjlm1Mxd17WgghmQBpiFa-uI5FIwQqhqpTTMSiGN42fodue7HZqNbY0NfYJOb5PfQHrTEbz-Xwl-pZfxVbNyBBHF4MfeIMW_g8293vg8fgGCjUPWouQILmUBf-5Ak2LOybpDCCV6XIMua9DjGjQv8Ld_2zqg-7kX_WKvQy7jdAmC8fmAsZpTNRubu9xhuShhaZNexyGFMtCPQ7_v6AD9kOzBrSAjwfk7D8yqBQ</recordid><startdate>199701</startdate><enddate>199701</enddate><creator>Jayson, GC</creator><creator>Gallagher, JT</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>199701</creationdate><title>Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells</title><author>Jayson, GC ; Gallagher, JT</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-b3da81a54d8e38b1dcff2c94f6557172ca8ca2ea6ef0838720019d88c2e878cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Caco-2 Cells</topic><topic>Cancer Research</topic><topic>Cattle</topic><topic>Cell Division - drug effects</topic><topic>Cell Movement - drug effects</topic><topic>Chlorates - pharmacology</topic><topic>Chromatography, Gel</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>experimental-oncology</topic><topic>Fibroblast Growth Factor 2 - antagonists &amp; inhibitors</topic><topic>Fibroblast Growth Factor 2 - pharmacology</topic><topic>General aspects</topic><topic>Glycosaminoglycans - metabolism</topic><topic>Heparin - analogs &amp; derivatives</topic><topic>Heparin - chemistry</topic><topic>Heparitin Sulfate - pharmacology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Molecular Medicine</topic><topic>Oligosaccharides - chemical synthesis</topic><topic>Oligosaccharides - isolation &amp; purification</topic><topic>Oligosaccharides - pharmacology</topic><topic>Oncology</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jayson, GC</creatorcontrib><creatorcontrib>Gallagher, JT</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jayson, GC</au><au>Gallagher, JT</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1997-01</date><risdate>1997</risdate><volume>75</volume><issue>1</issue><spage>9</spage><epage>16</epage><pages>9-16</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>A number of growth factors, including members of the fibroblast growth factor (FGF) family - hepatocyte growth factor, vascular endothelial growth factor and heparin-binding epidermal growth factor - are dependent on heparan sulphate (HS) for biological activity mediated through their high-affinity signal-transducing receptors. This obligate requirement for HS prompted the search for antagonists of HS function that could be used as anti-growth factor drugs for the treatment of cancer. Basic FGF (bFGF) was the focus of this study. Caco-2, a human colon carcinoma cell line, was adapted to growth in serum-free medium so that investigation of its growth factor requirements for growth and migration could be performed in defined conditions (Jayson GC, Evans GS, Pemberton PW, Lobley RW, Allen T 1994, Cancer Res, 54, 5718-5723). This cell line multiplied and moved in a dose-dependent manner in response to bFGF. Here, we show that the mitogenic response to bFGF is dependent on the presence of heparan sulphate. A library of heparin oligosaccharides with uniform composition but variable length was generated [general formula [IdoA(2S)-GlcNS(6S)n], and oligosaccharides of defined lengths were tested for their ability to inhibit the biological activity of bFGF. While intact heparin and heparin-derived fragments of 12 monosaccharide units did not affect bFGF-induced cell division or bFGF-induced cell migration, octasaccharides and decasaccharides potently inhibited the bFGF-induced growth and migration responses. In particular, octasaccharides completely inhibited these biological activities at 10 microg ml-, a clinically achievable and tolerable concentration. This study shows that the length of an oligosaccharide determines its ability to block the biological activity of bFGF. The observation that the biological activity of cell-surface heparan sulphate can be antagonized in this way in a human carcinoma cell line suggests that oligosaccharides should be investigated further as anti-growth factor agents for the treatment of cancer. In addition, the results suggest that the clinical evaluation of low-molecular weight heparin (LMWH) as an anti-cancer agent might benefit from subfractionation of the LMWH, to remove oligosaccharides of 12 or more residues.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>9000592</pmid><doi>10.1038/bjc.1997.3</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 1997-01, Vol.75 (1), p.9-16
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2222707
source MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Animals
Antineoplastic agents
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Caco-2 Cells
Cancer Research
Cattle
Cell Division - drug effects
Cell Movement - drug effects
Chlorates - pharmacology
Chromatography, Gel
Drug Resistance
Epidemiology
experimental-oncology
Fibroblast Growth Factor 2 - antagonists & inhibitors
Fibroblast Growth Factor 2 - pharmacology
General aspects
Glycosaminoglycans - metabolism
Heparin - analogs & derivatives
Heparin - chemistry
Heparitin Sulfate - pharmacology
Humans
Medical sciences
Molecular Medicine
Oligosaccharides - chemical synthesis
Oligosaccharides - isolation & purification
Oligosaccharides - pharmacology
Oncology
Pharmacology. Drug treatments
title Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T02%3A42%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heparin%20oligosaccharides:%20inhibitors%20of%20the%20biological%20activity%20of%20bFGF%20on%20Caco-2%20cells&rft.jtitle=British%20journal%20of%20cancer&rft.au=Jayson,%20GC&rft.date=1997-01&rft.volume=75&rft.issue=1&rft.spage=9&rft.epage=16&rft.pages=9-16&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1997.3&rft_dat=%3Cproquest_pubme%3E78787388%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78787388&rft_id=info:pmid/9000592&rfr_iscdi=true